Riociguat Drug Asset Due Diligence Report 2026

This Riociguat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Riociguat can convert its Small molecule drug profile and sGC biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Riociguat (query alias: riociguat)
Modality / target	Small molecule drug; sGC; sGC stimulants
Highest global status	Approved
Originator	Bayer AG
Active developers	Bayer AG, Merck Sharp & Dohme LLC, Bayer Yakuhin Ltd.

The MCP disease footprint includes Hypertension, Pulmonary, Familial Primary Pulmonary Hypertension, Idiopathic pulmonary arterial hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07644377	Phase 3	Not yet recruiting	150	To evaluate whether the discontinuation of riociguat monotherapy after successful BPA in CTEPH patients is associated with an acceptably low risk of clinical worsening compared to continuation
CTR20251799	Not Applicable	已完成	72	Not disclosed
CTR20254271	Not Applicable	已完成	42	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

An Open-label, Prospective, Single Centre Study of the Effects of Riociguat on RIght VEntricular Size and Function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Phase 4; n=30; evaluation: not stated. Reported fields: Change in RV (Right Ventricular) Area(Mean) = -6.00 cm^2 (Standard Deviation, 3.80); Change in RV (Right Ventricular) Area(Mean): Mean Difference (Final Values) = -6.00(95% CI, -7.42 to -4.58), P-Value = <0.001; Change in RV (Right Ventricular) Area(Mean): Mean Difference (Final Values) = -6.00(95% CI, -7.42 to -4.58), P-Value = <0.001

EFFICACY AND SAFETY OF RIOCIGUAT IN EARLY PULMONARY ARTERIAL HYPERTENSION

Phase 2; n=35; evaluation: Positive. Reported fields: PVR = 0.89 WU ( 3.29); PVR = -0.69 WU ( 0.6)

Efficacy and Safety of Riociguat (MK-4836) in Incipient Pulmonary Vascular Disease as an Indicator for Early Pulmonary Arterial Hypertension Double-blind, Randomized, Multicenter, Multinational, Placebo-controlled Phase IIa Study (ESRA)

Phase 2; n=35; evaluation: not stated. Reported fields: Change of Pulmonary Vascular Resistance (PVR)(Mean) = 0.89 WU (Standard Deviation, 3.29); Change of Pulmonary Vascular Resistance (PVR)(Mean) = -0.69 WU (Standard Deviation, 0.60); Change of Pulmonary Vascular Resistance (PVR)(Mean): P-Value = 0.043; P-Value = 0.045

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Riociguat addresses Hypertension, Pulmonary, Familial Primary Pulmonary Hypertension, Idiopathic pulmonary arterial hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2014-05-06	Merck pays $1B to buy into Bayer's cardio future	Approved	US$1,000.0M upfront; US$1,100.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Stable riociguat compositions with improved genotoxic impurity profile”. The milestone feed surfaced a patent-application signal described as “Preparation method of riociguat tablet”. The milestone feed surfaced a patent-application signal described as “An improved process for the preparation of riociguat and its intermediate thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO